ALK is amplified in about 14 % of neuroblastomas and while responses occur, particularly in familial cases, resistance in most sporadic cases is high and the value of the ALK inhibitor crizitonib is reduced [2]. The gene discussed is ALK; the disease is neuroblastoma.